Obermatt
See Similar Stocks →

ABIVAX

PAR:ABVX · FR0012333284
BiotechnologySmall

360

26
Profit price63
Owner Earnings Yield1
Dividend Yield1
Price/Sales5
EV / Gross Profit4
Price/Book1
Return on Capital10
Cash Return on Capital10
Return on Equity6
Profit margins30
Accruals93
Owner Earnings Margin7
Sales growth11
Profit growth14
Reinvestment10
Price momentum100
Debt load59
Refinancing48
Debt Payback1
Liquidity44
Analyst ratings19
Opinion Changes50
Price Target Upside47
Market mood79
Value Creation0/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

ABIVAX doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Based on 3/5 components.

Profile

CountryFrance
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeENXTPA
Founded2013
Employees91
Websiteabivax.com
ISINFR0012333284
Last UpdateApr 2, 2026
Indices
CAC All (France)NASDAQ (USA)SBF 120 (France)
Themes
ImmunologyInflammationOncologyGastroenterologyChronic DiseasesBiotechnology

Description

ABIVAX Société Anonyme (Abivax) operates as a clinical-stage biopharmaceutical company. The company focuses on inflammatory bowel diseases (IBD), chronic conditions involving inflammation of the gastrointestinal tract, of which the two most common f…

Analysis

Middle-of-the-road

ABIVAX Société Anonyme is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is moderate and the balance sheet is adequate. The company scores 0/20 on our value-creation score: not creating value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
67
2026

All-time high

67

Jun 2026

All-time low

64

Mar 2026

Average rank

66

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
5
—
—
—
Price/Earnings
89
—
—
—
Price/Book
1
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
45
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare ABIVAX with its peers
Transgene
PAR:TNG
15
CountryFrance
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Basilea Pharmaceutica
SWX:BSLN
66
CountrySwitzerland
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Immatics
NAQ:IMTX
31
CountryGermany
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Kuros Biosciences
SWX:KURN
80
CountrySwitzerland
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
AC Immune
NMQ:ACIU
68
CountrySwitzerland
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
OKYO Pharma
NAQ:OKYO
40
CountryUK
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →